Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).

Phase 1/2 Unknown 10 enrolled University of Jordan

RandomizedSingle-groupOpen-labelTreatment

Summary

This study aims to examine the short term and long term safety outcomes of the treatment of PD patients with umbilical cord derived stem cells as indicated by the presence of adverse events that are confirmed to be related to the therapy.

Timeline

Start: 2018-06-01
Primary completion: 2020-07-30
Completion: 2021-09-20

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper Study chart implementation, data collection, and analysis are ongoing. PMID 34677138 ↗

Publications

Jamali F, Aldughmi M, Khasawneh MW, Dahbour S, Salameh AA, Awidi A. A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study. JMIR Res Protoc. 2021 Oct 22;10(10):e29695. doi: 10.2196/29695.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	human Wharton jelly-derived mesenchymal stem cells	Cell therapy	—	Intrathecal
Subject	neural stem cells	Cell therapy	—	Intrathecal